Boron dipyrromethene (BODIPY)-based photosensitizers for photodynamic therapy

TLDR

Photodynamic therapy, which relies on light, a photosensitizer, and oxygen, has proven effective for cancers and other localized diseases, and BODIPY-based agents have emerged as a promising new class studied over the past decade. This review summarizes a decade of research on BODIPY-based photosensitizers. The authors discuss the superior photophysical properties of BODIPY agents and the synthetic strategies that enhance their selectivity and targeting.

Abstract

Photodynamic therapy (PDT) has shown promise as an effective treatment modality for cancers and other localized diseases, such as age-related macular degeneration and actinic keratosis. PDT relies on light, photosensitizer and oxygen as elements in its mechanism of action. BODIPY photosensitizers that have been under extensive study over the past decade have been demonstrated as a new class of photosensitizers. In this review, we attempt to summarize the decade-long study of BODIPY-based photosensitizers. We provide an overview of the superior photophysical properties possessed by BODIPY-based agents and the various synthetic strategies employed that have led to improved and selective and/or targeted photosensitizers.